vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
cbdMD, Inc. is the larger business by last-quarter revenue ($5.0M vs $3.9M, roughly 1.3× Opus Genetics, Inc.). On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -10.2%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs 7.1%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
IRD vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $5.0M |
| Net Profit | — | $-283.1K |
| Gross Margin | — | 59.8% |
| Operating Margin | — | -5.7% |
| Net Margin | — | -5.6% |
| Revenue YoY | -10.2% | -1.9% |
| Net Profit YoY | 53.0% | -1975.7% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $5.0M | ||
| Q3 25 | $3.1M | $4.7M | ||
| Q2 25 | $2.9M | $4.6M | ||
| Q1 25 | $4.4M | $4.7M | ||
| Q4 24 | $4.3M | $5.1M | ||
| Q3 24 | $3.9M | $4.6M | ||
| Q2 24 | $1.1M | $5.2M | ||
| Q1 24 | $1.7M | $4.4M |
| Q4 25 | — | $-283.1K | ||
| Q3 25 | $-17.5M | $-680.0K | ||
| Q2 25 | $-7.4M | $-895.3K | ||
| Q1 25 | $-8.2M | $-480.8K | ||
| Q4 24 | — | $15.1K | ||
| Q3 24 | $-7.5M | $-152.8K | ||
| Q2 24 | $-7.8M | $459.7K | ||
| Q1 24 | $-7.1M | $-3.0M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 62.3% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 53.9% | ||
| Q2 24 | — | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | — | -5.7% | ||
| Q3 25 | -269.9% | -14.5% | ||
| Q2 25 | -309.0% | -19.6% | ||
| Q1 25 | -227.2% | -10.2% | ||
| Q4 24 | — | -1.7% | ||
| Q3 24 | -207.1% | -6.9% | ||
| Q2 24 | -748.9% | -7.4% | ||
| Q1 24 | -450.5% | -35.4% |
| Q4 25 | — | -5.6% | ||
| Q3 25 | -566.9% | -14.4% | ||
| Q2 25 | -257.5% | -19.4% | ||
| Q1 25 | -187.5% | -10.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | -194.6% | -3.4% | ||
| Q2 24 | -698.3% | 8.9% | ||
| Q1 24 | -415.3% | -68.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.24 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | — | ||
| Q2 24 | $-0.30 | $-0.15 | ||
| Q1 24 | $-0.29 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $9.0M |
| Total Assets | $50.2M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $3.4M | ||
| Q3 25 | $30.8M | $2.3M | ||
| Q2 25 | $32.4M | $1.1M | ||
| Q1 25 | $41.8M | $1.8M | ||
| Q4 24 | $30.3M | $2.0M | ||
| Q3 24 | $36.6M | $2.5M | ||
| Q2 24 | $41.4M | $2.4M | ||
| Q1 24 | $47.2M | $2.1M |
| Q4 25 | $15.3M | $9.0M | ||
| Q3 25 | $6.0M | $7.2M | ||
| Q2 25 | $17.5M | $6.1M | ||
| Q1 25 | $5.1M | $665.8K | ||
| Q4 24 | $6.7M | $1.8M | ||
| Q3 24 | $34.3M | $2.0M | ||
| Q2 24 | $40.6M | $3.0M | ||
| Q1 24 | $46.1M | $3.1M |
| Q4 25 | $50.2M | $11.8M | ||
| Q3 25 | $36.1M | $10.4M | ||
| Q2 25 | $38.7M | $9.9M | ||
| Q1 25 | $48.2M | $10.9M | ||
| Q4 24 | $36.9M | $11.5M | ||
| Q3 24 | $40.4M | $10.6M | ||
| Q2 24 | $44.8M | $13.8M | ||
| Q1 24 | $51.8M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-812.5K |
| Free Cash FlowOCF − Capex | — | $-977.3K |
| FCF MarginFCF / Revenue | — | -19.5% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-812.5K | ||
| Q3 25 | $-6.2M | $-240.7K | ||
| Q2 25 | $-10.3M | $-704.2K | ||
| Q1 25 | $-9.0M | $-189.5K | ||
| Q4 24 | $-25.6M | $-317.9K | ||
| Q3 24 | $-5.1M | $167.4K | ||
| Q2 24 | $-7.3M | $289.8K | ||
| Q1 24 | $-5.7M | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | — | $-243.6K | ||
| Q2 25 | — | $-705.7K | ||
| Q1 25 | — | $-205.0K | ||
| Q4 24 | — | $-482.3K | ||
| Q3 24 | — | $157.4K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | — | -15.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | — | -9.4% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -16.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRD
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
